We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In this episode of ETF Spotlight, I speak with Brad Loncar, CEO of Loncar Investments, index provider for the Cancer Immunotherapy ETF (CNCR - Free Report) and the China BioPharma ETF .
2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space. Scientists were able to develop safe and effective COVID-19 vaccines in record time. Two of these vaccines, developed by Moderna (MRNA - Free Report) and BioNTech (BNTX - Free Report) in partnership with Pfizer (PFE - Free Report) , use a new technique called mRNA.
Unlike old-fashioned vaccines, which introduce a dead or weakened virus into the body, mRNA vaccines teach cells how to make a protein similar to one found on the virus, for triggering the body’s immune reaction. Can this powerful technology be used for treating other diseases?
Emmanuelle Charpentier and Jennifer Doudna won the Nobel Prize in Chemistry last year for their work developing the CRISPR, gene-editing technology. What is CRISPR? Can CRISPR and other gene-editing technologies be used to battle viruses and cure genetic diseases?
Brad likes Moderna, BioNTech, Translate Bio (TBIO - Free Report) and CureVac (CVAC - Free Report) for investing in mRNA, and while he is very bullish on the CRISPR technology, he is bearish on popular gene-editing stocks like CRISPR Therapeutics (CRSP - Free Report) and Editas (EDIT - Free Report) . Tune into the podcast to learn more.
CHNA is the best performing China focused ETF this year and it is also the top performer in the healthcare space. Why should investors look at China’s pharmaceutical and biotech industry?
Broad biotech ETFs like the iShares Nasdaq Biotechnology ETF (IBB - Free Report) and SPDR S&P Biotech ETF (XBI - Free Report) are also worth a look as they offer a safer way of investing in this volatile space with high growth potential.
Make sure to be on the lookout for the next edition of the ETF Spotlight! If you have any comments or questions, please email podcast@zacks.com.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Disclosure: Neena owns IBB and XBI in the ETF Investor Portfolio.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Best Biotech Stocks & ETFs for mRNA, Gene Editing
In this episode of ETF Spotlight, I speak with Brad Loncar, CEO of Loncar Investments, index provider for the Cancer Immunotherapy ETF (CNCR - Free Report) and the China BioPharma ETF .
2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space. Scientists were able to develop safe and effective COVID-19 vaccines in record time. Two of these vaccines, developed by Moderna (MRNA - Free Report) and BioNTech (BNTX - Free Report) in partnership with Pfizer (PFE - Free Report) , use a new technique called mRNA.
Unlike old-fashioned vaccines, which introduce a dead or weakened virus into the body, mRNA vaccines teach cells how to make a protein similar to one found on the virus, for triggering the body’s immune reaction. Can this powerful technology be used for treating other diseases?
Emmanuelle Charpentier and Jennifer Doudna won the Nobel Prize in Chemistry last year for their work developing the CRISPR, gene-editing technology. What is CRISPR? Can CRISPR and other gene-editing technologies be used to battle viruses and cure genetic diseases?
Brad likes Moderna, BioNTech, Translate Bio (TBIO - Free Report) and CureVac (CVAC - Free Report) for investing in mRNA, and while he is very bullish on the CRISPR technology, he is bearish on popular gene-editing stocks like CRISPR Therapeutics (CRSP - Free Report) and Editas (EDIT - Free Report) . Tune into the podcast to learn more.
CHNA is the best performing China focused ETF this year and it is also the top performer in the healthcare space. Why should investors look at China’s pharmaceutical and biotech industry?
Broad biotech ETFs like the iShares Nasdaq Biotechnology ETF (IBB - Free Report) and SPDR S&P Biotech ETF (XBI - Free Report) are also worth a look as they offer a safer way of investing in this volatile space with high growth potential.
Make sure to be on the lookout for the next edition of the ETF Spotlight! If you have any comments or questions, please email podcast@zacks.com.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Disclosure: Neena owns IBB and XBI in the ETF Investor Portfolio.